Raymond James Financial’s Charles River Laboratories CRL Stock Holding History

Raymond James Financial’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.4M	Buy	193,532 +71,278	+58%	+$13.2M	0.01%	1125
2025 Q4	$24.4M	Buy	122,254 +99,976	+449%	+$18.1M	0.01%	1303
2025 Q3	$3.49M	Sell	22,278 -3,084	-12%	-$490K	﹤0.01%	2738
2025 Q2	$3.85M	Sell	25,362 -197,597	-89%	-$26.3M	﹤0.01%	2553
2025 Q1	$33.6M	Sell	222,959 -8,761	-4%	-$1.47M	0.01%	956
2024 Q4	$42.8M	Buy	+231,720	New	+$44.6M	0.02%	810

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Raymond James Financial's CRL Position: Q1 2026 in Review

Raymond James Financial increased its Charles River Laboratories (CRL) stake by 58% in Q1 2026, buying an estimated $13.2M and bringing the position to 193,532 shares worth $33.4M. The position accounts for 0.01% of the portfolio, ranked #1125.

Raymond James Financial first reported a position in CRL in Q4 2024 and has held it in 6 quarters since. The position peaked at $42.8M in Q4 2024. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Raymond James Financial held 193,532 shares of Charles River Laboratories worth $33.4M as of Q1 2026.
Raymond James Financial bought 71,278 Charles River Laboratories shares in Q1 2026, an estimated $13.2M.
Charles River Laboratories made up 0.01% of Raymond James Financial's portfolio in Q1 2026, its #1125 holding.
Raymond James Financial first reported a position in Charles River Laboratories in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Charles River Laboratories position peaked at $42.8M in Q4 2024.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.